Wells Fargo raised the firm’s price target on GeneDx (WGS) to $155 from $140 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $200, named 2026 Top Pick at BTIG
- TSLA, META: Cathie Wood Dumps These Two Magnificent 7 Stocks, Doubles Down on Trade Desk (TTD) Instead
- WGS, WRD, IRDM: Cathie Wood Ramps Up Buying in GeneDx and WeRide, Trims Exposure in Iridium stock
- GeneDx price target raised to $160 from $140 at Piper Sandler
- GeneDx management to meet with Piper Sandler